Can-Fite BioPharma gets positive response from FDA to psoriasis pediatric plan

Can-Fite BioPharma announced that it received a positive response from the U.S. Food and Drug Administration FDA on the Pediatric Study Plan for the treatment of children suffering from psoriasis with Piclidenoson. The plan has been submitted to allow enrollment of children with psoriasis to Can-Fite’s upcoming Phase 3 pivotal clinical psoriasis studies, aiming at registration of Piclidenoson with both the FDA and the European Medicines Agency EMA for the treatment of plaque psoriasis.